Clinical application of probiotics in the treatment of Helicobacter pylori infection—A brief review  by Patel, Ami et al.
Journal of Microbiology, Immunology and Infection (2014) 47, 429e437Available online at www.sciencedirect.com
journal homepage: www.e- jmii .comBRIEF COMMUNICATIONClinical application of probiotics in the
treatment of Helicobacter pylori
infectiondA brief reviewAmi Patel*, Nihir Shah, J.B. PrajapatiDairy Microbiology Department, Sheth Mansukhlal Chhaganlal (SMC) College of Dairy Science, Anand
Agricultural University, Anand, Gujarat, IndiaReceived 5 December 2012; received in revised form 6 March 2013; accepted 28 March 2013
Available online 10 June 2013KEYWORDS
Eradication
treatment;
Gastritis;
Helicobacter pylori;
Interleukin-6;
Lactobacillus;
Stomach cancer* Corresponding author. Dairy Microb
University, Anand 388110, Gujarat, In
E-mail address: amiamipatel@yaho
1684-1182/$36 Copyright ª 2013, Taiw
http://dx.doi.org/10.1016/j.jmii.2013The role of probiotics in the treatment of gastrointestinal infections is increasingly being docu-
mented as an alternative or complement to antibiotics, with the potential to decrease the use
of antibiotics or reduce their side effects. Although antibiotics-based Helicobacter pylori erad-
ication treatment is 90% effective, it is expensive and causes antibiotic resistance associated
with other adverse effects. Probiotics have an in vitro inhibitory effect on H. pylori. Animal
studies demonstrated that probiotic treatment is effective in reducing H. pylori-associated
gastric inflammation. About 12 human studies investigated the efficacy of combinations of an-
tibiotics and probiotics, whereas 16 studies used probiotic alone as an alternative to antibiotics
for the treatment of H. pylori infection. Most of the studies showed an improvement of H. py-
lori gastritis and decrease in H. pylori colonization after administration of probiotics. Howev-
er, no study could demonstrate complete eradication of H. pylori infection by probiotic
treatment. Probiotic combinations can reduce adverse effects induced by H. pylori eradication
treatment and, thus, have beneficial effects in H. pylori-infected individuals. Long-term in-
takes of products containing probiotic strains may have a favorable effect on H. pylori infec-
tion in humans, particularly by reducing the risk of developing disorders associated with high
degrees of gastric inflammation.
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430 A. Patel et al.Introduction
For a long time, ulcers were considered to be a result of
stress and improper diet. The important discovery that ul-
cers are caused by a bacterial infection (Helicobacter py-
lori), which was rewarded with the 2005 Nobel Prize in
Medicine, has changed gastroenterological practice world-
wide. After its discovery, many gastroduodenal diseases
became curable infectious diseases. H. pylori is a highly
prevalent pathogen associated with chronic gastritis and
peptic ulcer, and is a risk factor for gastric malignancies.
The prevalence rate of H. pylori infection in the adult
population of industrialized countries is estimated to be at
20e50% and in developing countries, the rate is as high as
80%.1 H. pylori colonizes the stomach and induces chronic
gastritis, a long-lasting inflammation of the stomach. The
bacterium persists in the stomach for decades in many
cases. However, most infected people may never experi-
ence clinical symptoms despite having chronic gastritis;
10e20% of those colonized by H. pylori may ultimately
develop peptic ulcers.2 H. pylori infection is also associated
with 1e2% lifetime risk of stomach cancer and a less than
1% risk of gastric mucosa-associated lymphoid tissue (MALT)
lymphoma. This pathogen was designated as a class-I
carcinogen for stomach cancer in 1994, after epidemio-
logical investigation by the International Agency for
Research on Cancer (IARC), a subordinate organization of
the World Health Organization.3 The infection is generally
acquired during childhood and can persist indefinitely, if
not treated systematically.4 It has been suggested that H.
pylori infection rates vary with age, ethnicity, socioeco-
nomic status, sanitary environments, and lifestyle.5
None of the antimicrobials is effective enough to elimi-
nate H. pylori when given as a monotherapy; only a combi-
nation of these canwipe outH. pylori effectively.4 According
to Malfertheiner et al,6 the first-line recommended eradi-
cation treatment ofH. pylori consists of a combination of two
antimicrobials and an acid-suppressive drug. This triple
therapy used for the treatment of H. pylori has several
adverse effects, such as diarrhea, nausea, bloating, and
taste disturbance, possibly leading to discontinuation of the
treatment, and limited efficacy principally because of anti-
microbial resistance of the pathogen.7
Alternative anti-H. pylori treatments are currently
becoming more popular than the traditional eradication
methods. Components that may be used either as a mon-
otherapy or, synergistically, in combination with antimi-
crobials, resulting in a more effective anti-H. pylori
therapy or an alternative way of controlling H. pylori
infection, have been investigated in depth by several re-
searchers.2 It is believed that these novel therapies can
potentially cut down the costs related to the treatment of
H. pylori-associated diseases. One of the potential thera-
pies involves an application of probiotic cultures; promising
results have been observed in initial studies with numerous
probiotic strains. Nevertheless, many questions remain
unanswered. As defined by the Food and Agriculture Orga-
nization (FAO)/World Health Organization (WHO),8 pro-
biotics are live microorganisms that may confer a health
benefit on the host. The most commonly used probiotic
bacteria belong to the genera Lactobacillus andBifidobacterium, and these also include several yeasts such
as Saccharomyces boulardii.9
In the current article, the possible mechanisms of action
of probiotics on H. pylori infection, as reported by in vitro
cell line and animal studies, are narrated, followed by the
outcomes of the available in vivo evidences for the effect
of probiotics on H. pylori infection in humans. The effect of
the addition of probiotics to the standard H. pylori eradi-
cation therapy is also discussed.
Mechanisms of probiotic action on H. pylori
A number of mechanisms have been anticipated or hy-
pothesized from in vitro studies of host intestinal epithelial
or immune cell responses to probiotic strains. In that
context, probiotic bacteria can inhibit H. pylori by either
immunological or nonimmunological mechanisms. Accord-
ing to Haller et al,10 distinct probiotic strains may generate
divergent immune responses depending on the host’s im-
mune status.
Animal studies suggested that the immunomodulatory
effects of probiotic bacteria may be mediated through
immune regulation, particularly through controlling the
balance of proinflammatory and anti-inflammatory cyto-
kines and chemokines, which in turn would reduce gastric
activity and inflammation.11 Probiotic bacteria can bind to
recognition receptors, such as Toll like receptors (TLRs)
expressed on the surface of epithelial cells, and thus trigger
a cascade of immunological defense mechanisms.9 In that
TLR4 can recognize lipopolysaccharide of Gram-negative
bacteria, whereas TLR2 can recognize a variety of micro-
bial components, such as peptidoglycan and teichoic acids,
present in Gram-positive bacteria.12 The cytokine response
is initially manifested by the release of interleukin (IL)-8,
which leads to the migration of neutrophils and monocytes
to the mucosa.13 These activated monocytes and dendritic
cells stimulate production of various cytokines together
with IL-4, IL-5, IL-6, and interferon-g. According to Gill,14
probiotics can modify the immunologic response of the
host by interacting with epithelial cells and modulating the
secretion of anti-inflammatory cytokines, resulting in a
reduction of gastric activity and inflammation. In one of the
earlier studies, Kabir et al15 demonstrated that Lactoba-
cillus salivarius inhibits H. pylori-stimulated secretion of
IL-8 by gastric epithelial cells. During several animal
studies, a decrease in specific IgG antibodies to H. pylori
infection, parallel to a fall in gastric inflammation, was
observed following a probiotic intake.16,17 Also, enhance-
ment of secretory IgA production in the intestinal epithe-
lium may have a role in pathogen defense through
strengthening of the mucosal barrier.13,18 It was also
established that H. pylori infection induces production of
Smad7, nuclear factor (NF)-kB, IL-8, and tumor necrosis
factor-a in vitro. In a recent investigation, Yang et al19
observed that pretreatment of Lactobacillus acidophilus
at higher doses reduced H. pylori-induced inflammation
through the inhibition of H. pylori-induced Smad7 tran-
scription, by inactivating the Jak1 and Stat1 pathways, and
subsequently reduced nuclear NF-kB production.
Nonimmunological mechanisms of probiotics include
strengthening of mucosal barrier by producing
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Probiotics in the treatment of H. pylori 431antimicrobial substances, coaggregation with pathogens,
competing with H. pylori for adhesion receptors, stimu-
lating mucin production, and stabilization of the gut
mucosal barrier. Generally, probiotics such as lactic acid
bacteria (LAB) and bifidobacteria are able to produce
organic acids, hydrogen peroxide, carbon dioxide, and
some other antimicrobial compounds to inhibit potential
pathogens.20 Adhesion of pathogens can also be inhibited
by steric hindrance, where a large number of beneficial
bacteria may cover receptor sites in a non-specific manner,
or by competing for specific carbohydrate receptors that
would otherwise be available to pathogens. Several pro-
biotic species have shown growth inhibition or antiadhesion
ability against H. pylori in a gastric epithelial cell
model.16,21 Mucins, secreted by epithelial cells, may also
bind to pathogens, thereby inhibiting their adherence to
epithelial cells. Probiotics can interfere with the actions of
H. pylori, since several strains such as Lactobacillus plan-
tarum 299V and Lactobacillus rhamnosus GG have been
shown to induce mucin gene expression.22,23 Furthermore,
some Bifidobacterium strains have been found to release
heat-stable proteinaceous antimicrobial compounds against
H. pylori in vitro.24tm
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In the majority of studies dealing with either animal models
or humans, the most frequently used strains were Lacto-
bacillus johnsonii La1 and L. rhamnosus GG, either in a
fermented milk preparation containing live bacteria25e27 or
as a cell-free culture supernatant,28 followed by other
probiotics such as Lactobacillus casei, L. acidophilus,
Lactobacillus brevis and Lactobacillus gasseri OLL2716,
Lactobacillus reuteri, Bifidobacterium. lactis, Bifido-
bacterium animalis, Bifidobacterium breve, Propioni-
bacterium freudenreichii and probiotic yeast S. boulardii.
The effect of probiotics on H. pylori gastritis is commonly
measured by the rapid urease tests, urea breath test (UBT),
serological assays, stool antigen test, and histological ex-
amination of gastric biopsies.2,3,17,25e27
The outcomes of various in vitro and in vivo clinical
studies are discussed in the following sections. They have
been categorized as studies in experimental animals and
cell lines; and human studies, for better understanding the
effect of individual probiotic strain or combination of
thereof on H. pyroli infection.T
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cell lines
Various probiotics have shown favorable effects in animal
models of H. pylori infection (Table 1). In a few preliminary
studies, oral administrations of L. salivarius to H. pylori-
infected gnotobiotic BALB/c mice showed a highly protec-
tive and therapeutic effect.15,17 Similarly, Coconnier et al29
reported that L. acidophilus strain LB was able to protect
against H. pylori infection in conventional mice. In a
C57BL/6 mice model of infection, a probiotic combination
containing L. acidophilus R0052 and L. rhamnosus R0011
was found to reduce the effects of H. pylori infection
432 A. Patel et al.through reducing H. pylori colonization and alleviating H.
pylori-induced inflammation of the stomach.31 In a Mon-
golian gerbil model of H. pylori infection, the same pro-
biotic preparation was proved effective via its attenuating
effect on H. pylori colonization, mucosal inflammation, and
impairment of the gastrinesomatostatin link.33 Studies by
Sgouras and coworkers16,32 in a C57BL/6 mice model
demonstrated that L. casei strain Shirota and L. johnsonii
La1, both administered in drinking water, attenuated H.
pylori infection-induced gastric mucosa inflammation.
However, only L. casei strain Shirota was able to down-
regulate the colonization of H. pylori to gastric mucosa. In
another study, L. gasseri was found to decrease coloniza-
tion of clarithromycin-resistant H. pylori.30
The potential of recombinant Lactobacillus or any other
probiotics to be used as antigen-delivery vehicles to induce
protective immune responses has rarely been studied. A
recombinant L. plantarum strain producing H. pylori urease
B subunit was found to induce successfully a partial
mucosal protection against the pathogenic strain.34 By
contrast, in the study carried out by Lee et al,35 Lacto-
coccus lactis-producing cytoplasmic urease B was shown to
be unable to induce protection against H. pylori in a mouse
model.
Recently, Chen et al36 assessed the antagonistic activ-
ities of Lactobacillus strains against H. pylori growth in a
co-culture system and its infection in human gastric
epithelial cells. Results showed that the Lactobacillus
strains had significant anti-H. pylori activity, which can be
attributed to the cell-free supernatants of lactobacilli and
live Lactobacillus strains in vitro.Clinical studies on humans
Numerous clinical trials in humans for the treatment of H.
pylori infection have been documented (Table 2).25,37e47
The role of probiotics in the treatment of H. pylori infec-
tion is acknowledged either as a complement or as an
alternative to antibiotics, having the potential to decrease
the use of antibiotics. However, occurrence of side effects
is one of the major drawbacks of antibiotic treatment.
Gastrointestinal manifestations may be related to alter-
ations in the intestinal microflora. Probiotics can prevent or
reduce antibiotic-associated side effects and have an
inhibitory effect on H. pylori.2
In 2000, the first study on humans was conducted by
Canducci and coworkers,37 which provided evidence that
L. acidophilus LB improved the rate of H. pylori eradication
significantly in the probiotic group. However, the supple-
mentation did not alleviate the side effects of the anti-
Helicobacter treatment. In that connection, two separate
double-blind studies reported that L. rhamnosus GG was
able to reduce the occurrence of adverse effects including
diarrhea, nausea, and bloating, unlike the outcomes of the
previous study.38,39 Based on the results of an open and
uncontrolled clinical trial, Sheu et al40 reported that a
yoghurt containing L. acidophilus La5 and B. lactis Bb12
was able to increase the eradication rate and also decrease
some side effects of the triple therapy. In another study,
Cremonini et al41 observed that the administration of
L. rhamnosus GG, probiotic yeast S. boulardii, or acombination of L. acidophilus and B. lactis for 2 weeks also
decreased adverse events during the triple treatment. The
effects of a probiotic supplementation seemed to be in-
dependent of the probiotic species used. In a 10-day
quadruple anti-Helicobacter therapy with L. casei ssp.
casei DG, the supplementation improved significantly the
eradication rate in patients after failure of the first-line
eradication treatment.42 Similarly, in patients with H. py-
lori resistance, L. acidophilus La5 combined with B. lactis
Bb12 improved the second-line rescue therapy.45 Mylly-
luoma et al,25 in a randomized double-blind study, used a
combination of several probiotics and observed a decrease
in gastritis and H. pylori colonization in 118 individuals.
To date, only two studies have been conducted in
dyspeptic children. In the earliest study, fermented milk
products containing L. casei DN-114 001 were found to in-
crease the eradication rate of standard triple treatment
efficiently.43 The second study was carried out by Lionetti
et al,44 where L. reuteri was found to alleviate eradication
treatment, with associated adverse effects. In a recent
study of Ojetti et al47 conducted in H. pylori-positive pa-
tients, L. reuteri supplementation increased the eradica-
tion rate, at the same time decreasing the incidence of the
most common side effects associated with antibiotic ther-
apy in the second-line treatment.
Studies concerning the attenuation of microbiota dis-
turbances with probiotics following an anti-Helicobacter
triple treatment are limited. Madden and coworkers48
found that a probiotic combination, which included two
strains of L. acidophilus (CLT60 and CUL21) and two strains
of B. bifidum (CUL17 and B. bifidum Rhodia), stabilized the
number of facultative anaerobes. Later, Plummer et al49
reported that the same probiotic preparation was able to
diminish the amount of antibiotic resistance among
enterococci and reduce disruption of the enterobacterial
component in the regrowth population.
Probiotics as an alternative to antimicrobials have also
been the focus of several studies (Table 3).27,28,50e63
Initially, Mrda and coworkers50 studied the effect of aci-
dophilus milk containing live probiotic bacteria on 14 in-
dividuals and observed a decrease in H. pylori colonization,
with a simultaneous increase in the eradication rate.
Administration of a culture supernatant or fermented milk
containing the strain of L. acidophilus La1 was found to
decrease H. pylori urease activity, as measured by 13C-UBT
values in adults28 and children54; similar results were
observed in two other trials, as confirmed by histological
analysis.2,55 In the latter two studies, a decrease in
H. pylori infection-associated inflammation was evident.
However, none of the studies reported that regular intake
of L. acidophilus (johnsonii) La1 eradicated H. pylori. In a
study conducted by Sakamoto et al51 in 31 patients with H.
pylori infection, it was indicated that L. gasseri OLL2716
was effective in suppressing H. pylori and reducing gastric
mucosal inflammation, as measured by 13C-UBT values and
assays of serum pepsinogen I. Similar results were obtained
by Shimizu et al,53 using L. gasseri OLL2716 in 12 children.
In another study, L. casei was also shown to inhibit H. pylori
growth, as reflected by a reduction in 13C-UBT values.56
Similar effects on the growth of H. pylori were reported
by Wang et al58 in a study of 59 human volunteers
who consumed yoghurt containing L. acidophilus La5 and
Table 2 Clinical trials using probiotics as a complement during Helicobacter pylori eradication treatment
Patient group Study design Eradication therapy Probiotic strain Product, dose, time Results Reference
120 dyspeptic
adults
O, R CA þ rabeprazole Lactobacillus acidophilus
LB
Capsule, inactivated
bacteria, 1.5  1010
CFU/d, 10 d
Eradication rate [, side
effects4
Canducci et al37
60 asymptomatic
adults
O, R CT þ pantoprazole Lactobacillus rhamnosus
GG
Freeze-dried powder,
1.2  1010 CFU/d,14 d
Eradication rate4, side
effects Y
Armuzzi et al38
120 asymptomatic
adults
DBPC, R CT þ pantoprazole L. rhamnosus GG Freeze-dried powder,
1.2  1010 CFU/d, 14 d
Eradication rate4, adverse
effects [
Armuzzi et al39
160 dyspeptic
adults
O, R CA þ lansoprazole L. acidophilus La5 and
Bifidobacterium lactis
Bb12
Yoghurt, 1  1010 CFU/d,
4 wk
Eradication rate [, adverse
effects Y
Sheu et al40
85 asymptomatic
adults
DBPC, R CT þ rabeprazole L. rhamnosus GG,
Saccharomyces boulardii,
L. acidophilus La5, and
B. lactis Bb12
Freeze-dried powder,
1e1.5  1010 CFU/d,
2 wk
Eradication rate4, adverse
effects Y
by all probiotics
Cremonini et al41
70 dyspeptic adults
with resistant
Helicobacter pylori
R AT þ ranitidine
bismuth citrate
þ esomeprazole or
pantoprazole
L. casei ssp. casei DG Capsule, 1.6  1010
CFU/d, 10 d
Eradication rate4, adverse
effects Y
Tursi et al42
86 dyspeptic children DBPC, R CA þ omeprazole L. casei DN-114 001 Fermented milk, 1  1010
CFU/d, 2 wk
Eradication rate [, adverse
effects4
Sykora et al43
40 dyspeptic children DBPC, R A þ omeprazole 5 d
following CT
þ omeprazole 5 d
Lactobacillus reuteri
ATCC 55730
Capsule, 1  108 CFU/d,
20 d
Eradication rate4, adverse
effects Y
Lionetti et al44
138 dyspeptic adults
with resistant
H. pylori
O, R AM þ bismuth citrate
þ omeprazole
L. acidophilus La5 and
B. lactis Bb12
Yoghurt, 4  1010 CFU/d,
4 wk prior to eradication
treatment
Urease activity Y during
pretreatment, eradication
rate [, side effects Y
Sheu et al45
65 children R CA þ omeprazole Bifidobacterium animalis,
L. casei
250 mL yoghurt (107
CFU/mL)
Eradication rates [ Goldman et al46
118 individuals R, DBPC CA þ omeprazole LGG þ L. rhamnosus LC
þ Propionibacterium.
freudenreichii þ B. breve
Milk-based drink, 1  109
CFU/mL, twice a day
for 4 wk
followed by once a day
for 6 wk
Eradication4, urease
activity Y, gastritis and
H. pylori colonization Y
Myllyluoma et al25
90 individuals A þ esomeprazole
þ levofloxacin
L. reuteri Eradication rates [ Ojetti et al47
A Z amoxicillin; C Z clarithromycin; CFU Z colony forming units; DBPC Z double-blind placebo controlled; M Z metronidazole; O Z open; R Z randomized; T Z tinidazole;
[ Z increase; Y Z decrease;4 Z no effect.
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Table 3 Clinical trials using probiotics in the treatment of Helicobacter pylori infection
Patient group Study design Probiotic strain Product, dose, time Results Reference
14 patients O Lactobacillus acidophilus Acidophilus milk (3  250 mL/d)
4  109  1010 live
Eradication rate [, Helicobacter
pylori colonization Y
Mrda et al50
20 asymptomatic adults R, DB, PC L. acidophilus (jonhsonii) La1 Culture supernatant þ omeprazole,
dose NA, 14 d
Eradication4, urease activity Y,
H. pylori colonization4,
inflammation and gastritis4
Michetti et al28
52 asymptomatic adults R, DB, PC L. acidophilus (johnsonii) La1 Acidified milk þ clarithromycin,
dose NA, 3 wk
Eradication4, urease activity Y,
H. pylori colonization Y,
inflammation and gastritis Y
Felley et al27
31 asymptomatic adults PC Lactobacillus gasseri OLL2716 Yoghurt, 1.8e2.5  109 CFU/d,
8 wk
Serum pepsinogen I/II ratio [,
serum pepsinogen s Y, urease
activity Y
Sakamoto et al51
27 asymptomatic adults O Lactobacillus casei 03,
L. acidophilus 2412,
and L. acidophilus ACD1
Yoghurt, 2.8  1011 CFU/d, 30 d Urease activity4 Wendakoon
et al52
12 children O L. gasseri OLL 2716 (LG21 Yoghurt 120 g twice daily, 8 wk UBT Y, serum pepsinogen I/II ratio [,
HpSA level Y
Shimizu et al53
236 asymptomatic
children
R, DB, PC Living and heat-killed
L. acidophilus La1 or
Lactobacillus paracasei ST1
Fermented milk products, 1  1010
CFU/d, 4 wk
Eradication4, urease activity Y
by live La1
Cruchet et al54
50 asymptomatic adults R, DB, PC L. acidophilus (johnsonii) La1 Acidified milk, 1.25  109e10 CFU/d
16 weeks
Eradication4, H. pylori
colonization Y, inflammation Y,
and gastritis4
Pantoflickova
et al55
20 asymptomatic adults,
six adults in control
group
O, C L. casei Shirota Milk-based drink, 1.95  1010
CFU/day, 3 weeks
Eradication4, urease activity
tended to Y
Cats et al56
22 individuals R, DB, PC L .brevis CD2 Lyophilized bacteria in tablets
3 wk
Decrease in UBT, gastritis and
H. pylori colonization Y
Linsalata et al57
70 dyspeptic adults,
endoscopy for 14
individuals
O, C L. acidophilus La5 and
Bifidobacterium lactis Bb12
Yoghurt, 1  1010 CFU/d, 4 wk Eradication4, urease activity Y,
gastritis and H. pylori colonization Y
Wang et al58
254 asymptomatic children O, R L. acidophilus LB or
Saccharomyces boulardii with
inulin
Capsule or sachet, LB 1  1010
CFU/d, S. boulardii 500 mg þ 10 g
inulin/d, 8 wk
Eradication Y, S. boulardii with inulin
more effective than L. acidophilus LB
Gotteland et al26
295 asymptomatic
children (6e16 y)
R, DB, PC L. johnsonii La1 Cranberry juice (200 mL) and La1
product (80 mL) daily for 3 wk
Eradication rate [ when cranberry
juice and La1 given alone
Gotteland
et al59
79 individuals R, DB, PC Bifidobacterium bifium Beverage BF-1, 1  10712 wk Eradication rate [, DUBT Y, PG I
level Y
Miki et al61
33 patients and 40
asymptomatic
volunteers
R, DB, PC Lactobacillus reuteri SD2112 Tablets Reuterina Lower UBT, urease activity Y,
H. pylori density Y
Imase et al62
40 individuals R, DB, PC L. reuteri ATCC 55730 Once a day for 4 wk Suppresses H. pylori infection Francavilla et al63
CFUZ colony forming units; DBZ double blind; NAZ not available; OZ open; PCZ placebo controlled; RZ randomized; UBTZ urea breath test; [Z increase; YZ decrease;4Z no
effect.
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Probiotics in the treatment of H. pylori 435B. lactis Bb12 for 6 weeks. A randomized, double-blind,
placebo-controlled study conducted by Imase et al62 in 33
patients and 40 asymptomatic volunteers showed a signifi-
cant decrease in UBT values, which can be attributed to the
suppression of H. pylori urease activity and cell density by
L. reuteri. In 2008, Francavilla et al63 carried out a double-
blind study in 40 individuals, in which L. reuteri was found
to inhibit the growth of H. pylori.
Nevertheless, not all clinical trials have shown effec-
tiveness. In one open study, 27 H. pylori-infected volun-
teers received yoghurt containing three Lactobacillus spp.
and one commercial starter culture for 1 month, and, at the
end of the trial, 13C-UBT values remained positive in 26 of
the participants.52
Studies on the effect of synbiotics on H. pylori infection
remained very scarce. A randomized, open study investi-
gated the effects of L. acidophilus LB in comparison with
antibiotics and the synbiotic combination of probiotic yeast
S. boulardii with inulin.26 The eradication rate was slightly
better in the study group using S. boulardii combined with
inulin. In another study, Gotteland et al59 recorded similar
results with L. johnsonii La1, in 295 asymptomatic children,
using a mixture of cranberry juice (200 mL) and La1 product
(80 mL) as a synbiotic preparation.Safety aspects
Even though LAB have been granted generally recognized as
safe (GRAS) status by the WHO, each probiotic strain re-
quires a safety assessment. Different strains of probiotics
have different safety profiles, which should be taken into
account, and generalizations concerning all probiotics
should be avoided.60 Lactobacilli and bifidobacteria are
part of normal gastrointestinal microbiota, and systemic
infections with these bacteria may thus occur naturally,
unrelated to the ingestion of probiotics. Data on the safety
of probiotics suggest that probiotic therapy is generally
considered safe.60,64 A lethal dose (LD50) of LAB, as
measured for mice when administered orally, was found to
be >1011 CFU/kg, depending on the strain.65
Bifidobacteria have been found to be even safer because
no cases of sepsis related to probiotic ingestions have been
reported. The safety of two Bifidobacterium longum strains
of human origin was evaluated in healthy adult volunteers;
no side effects were reported and even the immune pa-
rameters measured remained stable, without any undesir-
able changes.66 Propionibacteria are also regarded as safe,
mainly because of their long history of safe use in Emmental
cheese manufacturing. Propionibacterium freudenreichii
ssp. shermanii has consequently been proposed to be
granted “Qualified Presumption of Safety” status by the
European Food Safety Authority.67
Safety considerations regarding antimicrobial resistance
are also taken into account while using probiotics. There
are questions about the possibility of resistance transfer
both from probiotics to pathogenic bacteria and from
commensal microbiota to probiotics. Probiotic strains are
generally susceptible to the majority of antibiotics,
although several studies have indicated that they can sur-
vive gastrointestinal transit reasonably well during antibi-
otic treatment.68 However, this did not lead to the transferof resistance genes from original microbiota to the ingested
probiotics.
In conclusion, the majority of the compiled studies
propose that consumption of certain strains of probiotics
may be useful in combating H. pylori infection as a com-
plement to the first- or second-line eradication therapy.
These probiotic strains are able to improve patient
compliance by reducing antibiotic-associated adverse
events, increasing the number of patients completing the
eradication therapy and resulting in an improved eradica-
tion rate. Complete eradication of H. pylori without an
anti-Helicobacter therapy has not succeeded; however,
regular consumption of probiotic products with specific
strains as an alternative to antibiotics may have some po-
tential in the suppression of H. pylori infection. In order to
further evaluate the potential efficacy of this probiotic
combination against H. pylori infection, studies comprising
a larger number of patients are necessary. It should be
possible to eradicate H. pylori infection with optimal effi-
cacy and tolerability to avoid excess use of antibiotics and
to offer alternative ways of controlling H. pylori infection if
eradication treatment is not recommended.Conflicts of interest
All contributing authors declare no conflicts of interest.References
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